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Abstract

To address the role of viral load in pathogenesis in patients with hantavirus
cardiopulmonary syndrome (HCPS), we quantified Sin Nombre virus S segment viral
RNA in plasma samples from 27 acutely-ill patients. For six patients we examined viral
load in matched plasma, urine, and/or tracheal aspirate throughout the time when patients
were in intensive care. Peak titers in plasma reached 1.8x106 copies/ml; none had viral
RNA in urine. Titers in tracheal aspirates did not exceed 8x104/ml. We found a
statistically significant association (P< 0.005) between plasma viral RNA levels at
admission and the severity of disease. Of those with plasma viral RNA titers above the
threshold for assay sensitivity (5000 copies/ml), those with mild-moderate and severe
disease had an average of 27,800 and 438,545 copies/ml, respectively. These results
suggest that patients with high viral loads on admission are more likely to have severe
disease.
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INTRODUCTION

Hantavirus (Bunyaviridas, Hantavirus) are rodent-borne viruses with a worldwide
distribution. Hantavirus cardiopulmonary syndrome (HCPS) is the human illness
associated with hantavirus infection in North and South America [1] [2]. HCPS has been
reported by at least nine nations from southern Patagonia to Canada. About 500 cases
have occurred in North America and several hundred cases each have been reported from
Argentina, Brazil and Chile since HCPS was first recognized in 1993. While some strains
of virus appear to be more virulent than others, the overall case fatality ratio for HCPS is
approximately 35-45 percent. Among the more virulent of the etiologic agents are Sin
Nombre virus (SNV) of the US and Canada and the “southern” or prototypical form of
Andes virus, which occurs in Chile and Argentina.

The pathogenesis of HCPS, like that of many other viral hemorrhagic fevers, is
little understood. The core abnormalities that define the pathogenesis generally include
capillary leak syndrome that selectively involves the pulmonary bed, noncardiogenic
pulmonary edema, thrombocytopenia, hypotension and/or cardiogenic shock. The long
incubation period for illness, the generally well-advanced adaptive immune response at
the time of onset of disease, and the apparent absence of direct lytic damage to vascular
endothelium are among the findings that have been taken as evidence that HCPS
pathogenesis is largely immune-mediated [3-6]. However, some workers have begun to
challenge this assessment, citing, for example, the ability of hantaviruses to directly
establish potentially maladaptive signaling cascades and to cause directly pathogenic
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effects on endothelial cells, such as impairing their ability to migrate across substrata, at
least in vitro [7-11].

A key question that would help to establish a potential role for antiviral
intervention in therapy is whether viral load during acute illness can be associated with
adverse clinical outcome. A study that attempted to determine whether such an
association existed was able to correlate high viral RNA titers only with surrogate
markers of severity such as the severity of thrombocytopenia, but its power may have
been too limited to establish whether viral RNA titer is directly correlated with adverse
clinical outcome [4]. Another study that used a blinded study design showed that high
levels of neutralizing antibodies was associated with a favorable clinical progression in
patients with HCPS [12].

The advent of sensitive real time RT-PCR assays for SNV RNA quantitation
prompted us to reinvestigate the question of whether SNV RNA titer can be associated
with adverse clinical outcome in patients in the acute stages of SNV infection [13,14].
Using a larger panel of plasma samples than has previously been available, we have
determined that there does appear to be an association between the titer of SNV RNA and
disease severity in patients in the early stages of HCPS, and that viral RNA is of low
abundance or absent in tracheal aspirates and urine respectively.
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MATERIALS AND METHODS

Study subjects. Case-patients with SNV infection were treated at the University
of New Mexico Hospital. Informed consent was obtained from patients or their parents or
guardians, and human experimentation guidelines of the US Department of Health and
Human Services and the University of New Mexico Human Research Review Committee
were followed in the conduct of this research.
Patients were considered to have acute SNV infection on the basis of clinical
considerations along with the following serological criteria: the presence of IgMantibodies directed against the SNV N antigen and the presence of IgG antibodies against
the viral G1 antigen. The IgG response to the G1 antigen is highly specific for SNV
infection, enabling us to exclude patients who could potentially have been infected with
hantaviruses other than SNV [15,16].
Twenty-seven patients with acute SNV infection were enrolled. Patients were
categorized as having severe disease (pulmonary failure and hemodynamic compromise
requiring mechanical ventilation and/or extracorporeal membrane oxygenation (ECMO))
or mild-moderate disease (no cardiopulmonary failure and did not require mechanical
ventilation).

Collection and preparation of specimens. We collected plasma, tracheal
aspirate and urine samples from patients with acute SNV infection at University of New
Mexico Hospital. A 10-ml specimen of EDTA- anticoagulant blood was processed with
Sigma Diagnostics Histopaque-1077 kit to separate plasma and peripheral blood
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mononuclear cells. All samples were split into 1-ml aliquots and frozen at -80º C within 3
hours of collection.

Nested reverse transcription (RT)-PCR. We extracted RNA from body fluids
(plasma, tracheal aspirate and urine) using the Qiamp Viral RNA Mini Kit (Qiagen,
Valencia, Calif.). A 280 µl aliquot of body fluid was used for RNA extraction and the
RNA was suspended in a volume of 70 µl. Total RNA derived from 40-µl aliquots of
plasma, tracheal aspirate and urine was loaded in each PCR reaction. We carried out RTPCR with nested primers for the small (S) genomic segment of SNV as described by
Botten et al [13]. The coordinates of the outer primers were positions 167 and 423 on the
SNV S segment, with inner primers at 190 and 401.

Quantitative TaqMan RT-PCR. We used a Perkin-Elmer Applied Biosystems
(Foster City, Calif.) 7000 sequence detection system for triplicate RT-PCR assays. RT
was conducted with RNA derived from 20 µl of plasma or tracheal aspirate using an S
segment primer at coordinate 167. Five microliters of cDNA was removed for real-time
quantitative PCR using primers from positions 179 and 245 of the SNV S segment [14].
PCR was conducted at 95o for 10 min, followed by 40 repetitions of 95o for 10s, 50o for
10s, then 72o for 30s. In our experiments, a standard curve containing dilutions ranging
from 5 to 5x105 copies of template was used on each 96-well plate. All of our standard
curves produced a -0.995 or better correlation coefficient between the quantity of
template loaded and the log of the Ct value.
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Spiking controls. To ensure the efficiency of our RNA extraction and nested RTPCR processes, we spiked negative plasma and negative urine samples with supernatants
of infected Vero E6 cells containing 2, 10, 100, or 1,000 copies of total S segment RNA.
For experimental “spiking” of plasma or urine samples, we used particles from SNV
strain SN77734 that were propagated in Vero E6 cells to most closely mimic the form of
viral particles that we expected could be present in the samples from infected patients (R.
Xiao, unpublished data). Known amounts of viral RNA-equivalents, as determined by
TaqMan RT-PCR were added into negative-control plasma or urine samples in a volume
of 200 µl before we prepared RNA. We suspended the resulting RNA into a volume of 50
µl. Total RNA derived from 40 µl of the virally-spiked samples were loaded in each RTPCR reaction as described above.

Statistical analysis. Number of RNA copies was summarized with means and
standard deviations for triplicate assays. Viral RNA copies were compared between
patients with mild-moderate and severe diseases using the exact version of the Wilcoxon
rank sum test. P-values of < 0.05 were considered statistically significant.

RESULTS

Nested RT-PCR. Body fluids were collected at University of New Mexico
Hospital from six patients who were admitted with acute SNV infection between October
1999 and July 2000. For each patient with HCPS, we collected plasma, tracheal aspirate
and urine on the day of hospital admission (day zero of hospitalization) and daily
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thereafter, until the patient left the hospital’s intensive care unit. Matched specimens from
the six patients (patient I, II, III, IV, V and VI), including 38 plasma, 22 tracheal
aspirates, and 38 urine samples, were examined for the presence of Sin Nombre (SN)
viral RNA by nested RT-PCR (Table 1).
All six patients exhibited RNA viremia (defined here as the presence of viral
RNA, not infectious virus) in plasma samples. We found that viral RNA was present in
plasma samples from all six patients during at least the first four days of hospitalization.
Patient VI, who was in the intensive care unit for thirteen days and was the only patient
monitored after d5, was positive for SNV RNA from d0 to d7 in her plasma samples,
with no detectable viral RNA in her plasma samples on subsequent days (Table 1).
A 5-ml sample of tracheal aspirate was taken daily through the endotracheal tube
from the patients who required mechanical ventilation during hospitalization. Tracheal
aspirate samples from the four patients on mechanical ventilation were screened for viral
RNA by nested RT-PCR (Table 1). We were able to screen nine tracheal aspirate samples
from d0 to d10 while patient VI was in the intensive care unit. We found that her tracheal
aspirate samples were positive for viral RNA from d0 to d4, and there was no detectable
viral RNA in her tracheal aspirate starting at d5 (Table 1). We also examined three
tracheal aspirate samples collected within the first 48 hours after admission from another
three patients whose plasma samples exhibited detectable viral RNA. Of the three
samples examined by nested RT-PCR, all three tracheal aspirates displayed viral RNA
(data not shown).
To examine the sensitivity of our nested RT-PCR, we spiked human plasma and
urine samples from healthy individuals with known quantities of cell-free virus particles.
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With nested RT-PCR, our sensitivity thresholds were no more than 2 copies of viral RNA
from healthy human plasma and urine samples (Figure 1).
A panel of 38 urine samples from the six patients was examined for viral RNA by
nested PCR. We found that there was no detectable viral RNA present in any of the urine
samples. Attempts to produce amplification products from centrifuged urinary sediment
were also unsuccessful (N=3).

Quantitative RT-PCR. To examine the changes of viral RNA load as a function
of time in a patient during the acute phase of disease, we quantified viral RNA in plasma
and tracheal aspirate samples of the six patients with HCPS throughout the entire time
course (day zero of hospitalization to at least day 5 in the intensive care unit). Our
quantitative RT-PCR system was less sensitive than nested RT-PCR, but allowed us to
track viral RNA load at levels of ≥ 5,000 copies per ml.
All six patients had viral RNA in plasma, with peak titers ranging from 1.5 x 105
to 1.8 x 106 per ml, in all cases occurring within the first three days of hospitalization
(Table 1) (Figure 2). Four patients had viral RNA in tracheal aspirates with titers up to 8
x 104 per ml (Table 1). Peak vRNA titers for tracheal aspirates were also found in the first
three days of admission (Figure 2). Starting on day 2 or day 3 after hospital admission,
the number of viral RNA copies began to decrease in both plasma and tracheal aspirate
samples (Figure 2). We found that the number of viral RNA copies in tracheal aspirate
never exceeded the level of viral RNA load in plasma sample from a patient at any time
point examined, nor were there any instances in which viral RNA in tracheal aspirate was
detectable and undetectable in plasma (Figure 2).
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We also screened three tracheal aspirates taken within the first 48 hours after
admission from another three patients with HCPS and found that the number of viral
RNA copies in each of these specimens did not exceed the titer of 2 x 104 per ml (data
not shown).

Viral load in severe and mild-moderate cases. To ascertain whether there is an
association between the viral RNA load and the disease severity in patients with HCPS,
we studied 27 patients during the acute phase of the disease, including 17 patients with
severe disease and 10 patients with mild-moderate disease. Table 2 shows the geographic
distribution, age range, sex and clinical characteristics of the 27 patients. Plasma samples
were collected within the first 24 h of hospital admission (day zero) for 22 patients and
on day one for the remaining 5 patients.
By screening for the presence of negative-strand viral RNA by quantitative RTPCR, we examined the earliest available plasma samples in the mildly ill patients (class 0
and I), in comparison with those patients with severe illness (class II and III) (Figure 3).
Of those whose sample had levels of S segment negative-strand RNA above the cutoff for
assay sensitivity of 5000 copies/ml, those with mild-moderate and severe disease had an
average of 27,800 and 438,545 copies/ml, respectively. Looking at all patients, we
observed that the median number of viral RNA copies was higher for patients with severe
disease as compared to those with mild-moderate disease (p < 0.005).
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DISCUSSION

Our study demonstrates a statistically significant association (P<0.005) between
the titer of SNV RNA and the disease severity in patients in the early stages of HCPS.
This finding is in contrast to a previous study by Terajima et al in 1999 where it was not
possible to show an association between viremia and disease severity, although it was
possible to show an association between load and surrogate lab markers for severity [4].
In this study, we studied plasma viral RNA load by quantitative TaqMan RT-PCR, which
is a relatively robust and sensitive technique that has been used extensively in rodent
SNV infection models with reproducible results [13,14,17]. Samples sizes were too small
to be certain that the results of Terajima et al in 2003 are in conflict with those report
here, and there were other important methodologic differences [5].

Our findings on the association between viral load in plasma and disease severity
indicate that those patients with high viral loads on admission are more likely to have a
severe course of disease. Previously we showed that a high-titer neutralizing antibody
response early in the course of hospitalization may be a predictor of a non-fatal outcome
in SNV infection [12]. It is possible that variations in viral load are related to variations
among titers of neutralizing antibody, but additional studies will be needed to further
clarify this relationship. The premise that the pathogenesis of HCPS is immune-mediated
is widely cited by workers in the field [2]. However, the present study suggests that
ongoing in vivo replication of SNV might still be an important determinant of disease
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severity. Therefore, level of viral load in patients during the early stages of HCPS might
eventually be used to monitor and/or predict the severity of clinical manifestations, which
vary from mild disease with stable hemodynamic status and minimal or no oxygen
requirement to fulminant progression and death due to cardiogenic shock. Markers
indicative of prognosis for patients with HCPS are needed to guide clinicians in deciding
whether triage to tertiary care centers or ECMO is appropriate. Currently only current
clinical status and the rate of change of clinical-laboratory findings are available as
guides. We anticipate the possibility that prompt determination of SNV viral load upon
admission may eventually guide clinicians toward more or less aggressive therapy.

Hantaviruses have been very difficult to isolate from human sources despite many
past attempts to do so. Using six plasma/tracheal aspirate specimen collected from HCPS
patients during the first day of hospitalization, we applied 1-ml of sample, either neat or
diluted at 1:5 in media, onto subconfluent Vero E6 cells and blind-passaged the cells for
4-6 wk, after which we screened the culture supernatants for the presence of viral RNA.
None was positive.

Our data on SNV load in body fluids demonstrated that SNV or SNV RNA appear
to be liberated into tracheal aspirates but not into urine in the patients with plasma
viremia. This finding has parallels with studies involving deer mice, where viral RNA
could be detected in the rodents’ saliva but not in urine [17]. These findings are
undertaken in part to allow comparisons between SNV, which is not transmitted
nosocomially, and the closely-related Andes virus which has been transmitted in hospitals
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by an unknown route [18], and person-to-person transmission of Andes virus likely
occurs during the prodromal phase or shortly thereafter [19].

Whether ongoing replication of SNV is an important factor in the pathogenesis of
HCPS is not well understood. Using a panel of plasma samples and a real time RT-PCR
assay, we have shown an association between the titer of SNV RNA and disease severity
in patients in the early stages of HCPS, and that viral RNA is of low abundance or absent
in tracheal aspirates and urine respectively. By contrast, preliminary studies with Andes
hantavirus infections in Chile suggest that plasma viral loads are too often below the limit
of detection of the assay to be useful in prediction of disease severity (M. Ferres, personal
communication). In order to place our present findings in context, further studies are
needed to determine the mechanisms by which SNV replication is regulated during acute
SNV infection, define the cell-mediated immune response, and gain more understanding
on how SNV is recognized by both the innate and acquired immune systems.
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Figure Legends:

Figure 1: Viral RNA spiking experiments. Viral supernatants of SN77734-infected
cultures that contained known numbers of copies of SNV S segment RNA were added
into negative serum samples before extraction of viral RNA. These RNAs were then used
in nested RT-PCR reactions.

Figure 2: SN viral RNA titers in plasma and tracheal aspirate samples of six patients with
HCPS. Negative-strand viral S segment RNA levels are expressed as copy numbers per
milliliter of plasma and tracheal aspirate. Error bars indicate the standard deviation for
triplicate. Threshold sensitivity was 5,000 copies/ml. Data is obtained from six patients
“patient I – VI”. Day of hospitalization is listed on the X-axis. Top panel shows results
for plasma samples. Bottom panel shows results for tracheal aspirates. “E” indicates that
the time points when the patient was on extracorporeal membrane oxygenation (ECMO).
NA, not available.

Figure 3: SN viral RNA titers in plasma samples of patients with severe and mildmoderate infections at hospital admission. Negative-strand viral S segment RNA levels
are expressed as copy numbers per milliliter of sample. Error bars indicate the standard
deviation for triplicate analyses. Threshold sensitivity was 5,000 copies/ml. Data were
obtained from 27 patients within 48 hours of admission.
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Table 1. Detection of viral RNA by nested RT-PCR and TaqMan RT-PCR in samples of
plasma and tracheal aspirate from six HCPS patients.
Patienta

Status

ID

Post

Presence of viral RNA by nested RT-PCR / Copies

admission

of RNA per ml (Mean ± standard deviation) by

day

TaqMan RT-PCR in indicated specimenb
Plasma

I

II

III

Severe

Severe

Severe

Tracheal aspirate

d0

+c / (151910 ± 24510)

NAd

d1

+ / (39820 ± 6420)

NA

d2

+ / (34900 ± 1300)

+ / (33310 ± 3302)

d3

+ / (17860 ± 1500)

+ / (5090 ± 2065)

d4

+ / NDe

-f / ND

d5

+ / ND

- / ND

d0am

+ / (738150 ± 33070)

NA

d0pm

+ / (324730 ± 40950)

NA

d1

+ / (441770 ± 34790)

NA

d2

+ / (112680 ± 4340)

NA

d3

NA

NA

d4

+ / (32100 ± 1440)

NA

d0

+ / (374950 ± 14120)

NA

d1

+ / (303370 ± 11730)

+ / (80430 ± 13116)

d2

NA

+ / (10960 ± 2798)

d3

+ / (33140 ± 640)

NA

d4

+ / (28060 ± 3340)

- / ND
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IV

V

VI

d5

+ / (13520 ± 400)

- / ND

d0

+ / (667720 ± 36450)

NA

d1

+ / (228620 ± 3860)

- / ND

d2

+ / (274720 ± 6650)

+ / ND

d3

+ / (243440 ± 28840)

- / ND

d4

+ / (230280 ± 39020)

- / ND

Mild-

d0

+ / (19110 ± 1040)

NA

moderate

d1

+ / (265400 ± 15010)

NA

d2

+ / (58490 ± 5150)

NA

d3

+ / (29510 ± 1830)

NA

d0

+ / (1815920 ± 66010)

+ / ND

d1

+ / (1623410 ± 7310)

+ / (8740 ± 926)

d2

+ / (281530 ± 640)

+ / ND

d3

+ / (71590 ± 10260)

+ / ND

d4

+ / (17060 ± 2680)

+ / ND

d5

+ / ND

- / ND

d6

+ / ND

- / ND

d7

+ / ND

NA

- / ND

- / ND

- / ND

NA

Severe

Severe

d8, d9 and
d10
d11 and
d12

20

a
b

Age range of patients, 23- 46. Sex ratio M: F, 3: 3.
No viral RNA detected in any of the urine samples.

c

Indicates the presence of viral RNA detected by nested RT-PCR.

d

NA, not available.

e

ND, not detectable by TaqMan RT-PCR.

f

Indicates no viral RNA detected by nested RT-PCR.

Table 2. Demographic and clinical characteristics of 27 patients with acute SNV
infection.
State of

Severity a:

Date of

infection:

number of

collection :

male (M) and

number of

patients

number of

female (F)

samples

patients

patients

Age (year)

Sex: Number of

NM: 18

Class 0: 1

Day 0: 22

Range: 11 – 63

M: 11

AZ: 5

Class I: 9

Day 1 : 5

Mean: 39

F: 16

CO: 3

Class II: 9

KS: 1

Class III: 8

a

Severity scale: Class 0, no cardiopulmonary manifestations; Class I: pulmonary edema

not requiring endotracheal intubation; Class II: survived, but required endotracheal
intubation; Class III: died. For the purpose of this study, patients in classes 0 and I were
considered mild-moderate cases, and those in classes II and III were considered severe
cases.
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